W

Walvax Biotechnology Co Ltd
SZSE:300142

Watchlist Manager
Walvax Biotechnology Co Ltd
SZSE:300142
Watchlist
Price: 12.76 CNY -2.45% Market Closed
Market Cap: 20.4B CNY
Have any thoughts about
Walvax Biotechnology Co Ltd?
Write Note

Walvax Biotechnology Co Ltd
Total Other Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Walvax Biotechnology Co Ltd
Total Other Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Other Income CAGR 3Y CAGR 5Y CAGR 10Y
W
Walvax Biotechnology Co Ltd
SZSE:300142
Total Other Income
ÂĄ78.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
27%
Beigene Ltd
HKEX:6160
Total Other Income
ÂĄ2.6B
CAGR 3-Years
N/A
CAGR 5-Years
440%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Total Other Income
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Total Other Income
-ÂĄ6.8m
CAGR 3-Years
14%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Total Other Income
-ÂĄ21.1m
CAGR 3-Years
34%
CAGR 5-Years
16%
CAGR 10-Years
N/A
Imeik Technology Development Co Ltd
SZSE:300896
Total Other Income
-ÂĄ2.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Walvax Biotechnology Co Ltd
Glance View

Market Cap
20.5B CNY
Industry
Biotechnology

Nestled within China's burgeoning biotechnology sector, Walvax Biotechnology Co Ltd has emerged as a formidable player in the field of vaccine development and production. Founded in 2001, the company has adeptly positioned itself to address the pressing health care needs in China and beyond. As a modern biopharmaceutical manufacturer, Walvax combines cutting-edge research with robust manufacturing capabilities, focusing primarily on the development of human vaccines. Its portfolio encompasses vaccines for a variety of infectious diseases, including those that target influenza, pneumonia, and rotavirus, allowing it to carve out a significant niche in the industry. By leveraging partnerships with global research institutions and investing heavily in R&D, Walvax continually enhances its product offerings, ensuring that they remain at the forefront of vaccine technology. This concerted focus on innovation and quality allows Walvax not only to address the existing public health challenges but also to anticipate future needs. Financially, Walvax operates through a well-oiled revenue model primarily driven by its sales of vaccines to both domestic and international markets. The company has crafted a streamlined supply chain, ensuring wide accessibility and distribution of its products. Through strategic pricing and partnerships with healthcare providers and government agencies, Walvax ensures steady revenue inflows, enabling continued investment in research and expansion. With China's focus on improving health care infrastructure and rising global awareness regarding the importance of vaccines, Walvax finds itself in an advantageous position. The company's ability to swiftly respond to market demands and regulatory requirements has further solidified its status as a key contributor to public health and a linchpin in the fight against infectious diseases.

Intrinsic Value
15.65 CNY
Undervaluation 18%
Intrinsic Value
Price
W

See Also

What is Walvax Biotechnology Co Ltd's Total Other Income?
Total Other Income
78.3m CNY

Based on the financial report for Jun 30, 2024, Walvax Biotechnology Co Ltd's Total Other Income amounts to 78.3m CNY.

What is Walvax Biotechnology Co Ltd's Total Other Income growth rate?
Total Other Income CAGR 10Y
27%

Back to Top